This inventor holds 5 USPTO granted patents and 16 published patent applications, plus 1 CIPO patent and 2 EPO patents. Top assignees: Endo Pharmaceuticals Inc., Gruenenthal Gmbh, Grunenthal Gmbh. Active years: 2011-2018.
Location History:
- Eschweiler, DE (2011 - 2012)
- Inden-Altdorf, DE (2015 - 2018)
Company Filing History:
2 out of 32 
2 out of 361 
1 out of 107 
Years Active: 2011-2018
Title: Dagmar Lischke: Innovator in Pharmaceutical Chemistry
Introduction
Dagmar Lischke is a prominent inventor based in Eschweiler, Germany. She has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of novel crystalline forms of compounds used in analgesics and other medical applications. With a total of two patents to her name, Lischke's work is recognized for its potential impact on pain management and treatment of urinary incontinence.
Latest Patents
Lischke's latest patents include innovative formulations that enhance the efficacy of pharmaceutical compounds. The first patent focuses on crystalline forms of (1RS,3RS,6RS)-6-dimethylaminomethyl-1-(3-methoxyphenyl)cyclohexane-1,3-diol hydrochloride. This invention relates to solid crystalline forms of the compound, methods of producing it, and its use as an analgesic. The second patent introduces a previously unknown crystalline form of (−)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride. This patent details pharmaceutical compositions containing the new crystalline form, methods of production, and its application in treating pain and urinary incontinence.
Career Highlights
Lischke is currently employed at Grünenthal GmbH, a company known for its focus on pain management and innovative pharmaceutical solutions. Her work at Grünenthal has allowed her to contribute to the development of important therapeutic agents that address significant medical needs.
Collaborations
Lischke collaborates with her coworker, Helmut Buschmann, to further advance their research and development efforts in the pharmaceutical field. Their partnership exemplifies the collaborative spirit that drives innovation in scientific research.
Conclusion
Dagmar Lischke's contributions to pharmaceutical chemistry through her patents and work at Grünenthal GmbH highlight her role as an influential inventor in the industry. Her innovative approaches to drug formulation have the potential to improve patient outcomes significantly.